Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 159

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 8
Chunk 159
---
 of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN FLX™ LAAC Device and our WATCHMAN FLX™ Pro LAAC Device, as well as our coronary therapies franchise led by the ongoing U.S. launch of our AGENT™ Drug-Coated Balloon. In the second quarter of 2025, we announced the discontinuation of worldwide sales of the ACURATE Neo2™ and ACURATE Prime™ Aortic Valve Systems and that we would no longer pursue U.S. FDA approval for ACURATE or approval in other geographies. We made the decision based on discussions with regulators which had resulted in increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new regions. The additional investments needed to satisfy these requirements were prohibitive and we will instead focus our resources and efforts on the remainder of the portfolio.

44

Peripheral Interventions 

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Net sales of Peripheral Interventions products of $698 million during the second quarter and $1.354 billion during the first six months of 2025 represented 14 percent of our consolidated net sales in both periods. Peripheral Interventions net sales increased $108 million, or 18.3 percent, during the second quarter and $190 million, or 16.4 percent, during the first six months of 2025, compared to the prior year periods. During the second quarter of 2025, this increase included operational net sales growth of 17.1 percent and the positive impact of 110 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2025, this increase included operational net sales growth of 16.5 percent and a negative impact of 10 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth included organic net sales growth of 7.0 percent during the second quarter of 2025 and 7.2 percent during the first six months of 2025, and the positive impact of 1,020 and 930 basis points, respectively, from our acquisition of Silk Road Medical during the third quarter of 2024 and Intera during the second quarter of 2025. Organic net sales growth in both periods was primarily driven by our interventional oncology franchise led by our Therasphere™ Y